1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Levitee Labs Inc.

Levitee Labs Inc.

LVT.CN
Levitee Labs Inc.CA flagCanadian Securities Exchange
0.01
CAD
- -
- -
502,089.00Market Cap
Levitee Labs Inc.
LVT.CN
(Canadian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
TTM
FRC
- -
0.04
0.11
Revenue per Share
-0.01
-0.27
-0.16
Basic EPS, GAAP
- -
-0.15
-0.12
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
- -
0.2
0.07
Book Value per Share
- -
0.02
-0.02
Tangible Book Value per Share
80
41
68
Basic Weighted Avg Shares
- -
2
8
Sales/Revenue/Turnover
- -
-638.7
-134.81
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
-11
-11
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
-662.39
-143.11
Profit Margin (%)
- -
- -
-3
Working Capital
- -
1
- -
LT Debt
- -
9
6
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
-275.44
-459.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'22
Jun'22
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
70
76
Market Capitalization
24
4
1

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'22
Jun'22
Total Current Assets
3
3
3
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
2
1
1
Total Current Liabilities
5
6
6
Payables & Accruals
2
2
3
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
5,509.27%
Free Cash Flow
- -
- -
3,766.25%
Net Income, GAAP
- -
- -
2,481.38%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
2
2
2022
2
1
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-0.01
2021
-0.01
-0.01
-0.06
- -
-0.27
2022
-0.04
-0.04
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Baotou Dongbao Bio-Tech Co.,Ltd (300239.SZ)
Legacy Technology Holdings, Inc. (LTHO)
China National Medicines Corporation Ltd. (600511.SS)
Laxai Pharma, Ltd. (LAXAF)
Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS)
Business
Levitee Labs Inc. (Ticker: LVT.CN) develops and commercializes innovative health and wellness products focused on natural remedies and nutraceuticals. The company offers a portfolio of cannabinoid-infused beverages, topical creams, and oral supplements under its proprietary brands, including Levitee-branded functional drinks designed for stress relief, sleep support, and cognitive enhancement; precision-formulated CBD oils and gummies targeting pain management and anxiety reduction; and advanced delivery systems such as nano-emulsified tinctures for improved bioavailability. These products cater to health-conscious consumers in the wellness and alternative medicine segments, with distribution through e-commerce platforms, specialty retailers, and direct-to-consumer channels primarily in Canada and select international markets. Founded in 2020 and headquartered in Vancouver, British Columbia, Canada, Levitee Labs operates as a publicly traded entity on the Canadian Securities Exchange with no disclosed parent company or major subsidiaries. In the past year, the company announced a strategic partnership with a leading European distributor to expand cannabinoid beverage sales into the EU market, completed a C$5 million funding round to support new product launches including a line of mushroom-infused adaptogen blends, and underwent a corporate rebranding initiative to emphasize its focus on science-backed levitation wellness technologies.